January 13th, 2003 — TissueInformatics.Inc — "The Tissue Information Company®".
Pittsburgh, PA-

TissueInformatics.Inc announced today that it has received a Notice of Allowance from the U.S. Patent office for a key patent application for the robust detection and quantification of stain binding in traditional tissue sections and tissue cores of Tissue Microarray (TMA) slides.

As allowed, this Patent will protect for a method of measuring or analyzing the amount of one or more stains on a tissue specimen by a process of transforming the color image of the specimen to define a stain curve that enables calculation of the amount of stain. The Patent will also cover a method of measuring the density and distribution of specific tissue features through the quantitative analysis of intensity values obtained from a color image of the tissue specimen.

TissueInformatics has revolutionized the TMA analysis process by embedding its proprietary quantification of Stain Absorption into its Tissue Microarray tissue analytic software — Arrayf(x). Arrayf(x) enables the automated quantification, visualization and presentation of immunohistochemical (IHC) analytic results for individual tissue specimens within a Tissue Microarray. For each tissue core in a TMA, stain intensity and percent area of staining may be measured and compared to a reference core enabling tissue cores with specific antibody binding to be identified.

TissueInformatics has also further expanded the scope of TMA Analysis by being the first in the industry to enable full quantitative analysis of specific structural elements within each Tissue Core. Tissue elements such as cells, angiogenic vasculature, and matrix organization may be identified and a range of feature metrics measured, such as type, shape, size and distribution. Tissue feature measurement data from the automated analysis of TMAs may now be automatically tabulated, graphically displayed and made available for correlation with other proteomic and genomic datasets.

"The methods covered by these allowed claims are important steps in the processing of tissue specimen images for a range of analytical applications. We believe the invention covered by the Patent, as allowed, overcomes significant obstacles to automated tissue analysis" said Dr. Peter Johnson, MD, TissueInformatics Chairman and CEO.

TissueInformatics (www.TissueInformatics.com) is the pioneer of automated hyperquantification analysis of normal and pathological tissue. TissueInformatics integrates sophisticated tissue imaging with its proprietary tissue analysis software to enable precise comparison of tissues for applications in drug discovery, correlative genomics with tissue morphology, automated toxicology, pre-clinical and clinical pharmacology, diagnostic and product safety applications, and quality assurance in tissue engineering.

The TissueInformatics TissueAnalytics™ Laboratory provides full tissue analysis service capabilities for animal trials and consists of a state of the art histology laboratory with multiple automated digital microscopes for high capacity slide imaging and analysis. Supported by certified veterinary and clinical pathologists and automated using TissueInformatics TissueAnalytics™ software, TissueInformatics performs client sponsored studies for the cost effective quantitative analysis of protein expression, correlative genomics with tissue morphology, angiogenesis, wound healing, liver pathology assessment and oncology.

###
Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with TissueInformatics.Inc's (the "Company's") dependence upon the creation of strategic alliances with providers for complementary services and products and the need to keep pace with rapid technological change, the Company's dependence for future revenues on its ability to increase sales of its tissue imaging and analysis applications, the development and availability of competitive products or technologies, and the Company's dependence on patents and its ability to defend its intellectual property rights. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook as of the date given.

Todd A. Joron
Senior Vice President
(412) 488-1100
TJoron@TissueInformatics.com

Back to Portfolio News